Inhalation of Hydrocortisone Acetate for Bronchial Asthma

Helm, W. H.; Heyworth, F

doi:10.1136/bmj.2.5099.768

Cited by 19 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early descriptions of asthma were of paroxysmal breathlessness which was later recognised to be due to bronchial hyperresponsiveness causing variable airways obstruction; therefore, initial treatments focused on agents that result in bronchodilatation, including theophylline, ephedrine and isoprenaline, and then more selective beta2-agonists, some of which are still used today [1,2]. Improvement in asthma symptoms with the use of corticosteroids in those with evidence of airways eosinophilia [3] led to more widespread use of corticosteroid treatment, with the subsequent development of inhaled corticosteroid (ICS) therapy [4,5], and the identification of eosinophilic inflammation in the airways as the major pathological process. In parallel, asthma management guidelines evolved to incorporate the earlier introduction of anti-inflammatory therapy to treatment regimes in a step-wise [6,7] manner within this paradigm.…”

Section: Introductionmentioning

confidence: 99%

Asthma Exacerbations in Severe Asthma: Why Systemic Corticosteroids May not Always Be the Best Treatment Option

McDowell

Busby

Heaney

2023

Curr Treat Options Allergy

View full text Add to dashboard Cite

Purpose Advances in the management of severe, eosinophilic asthma have improved, but asthma exacerbations continue to occur. This review aims to look at the evidence we have about why exacerbations may occur; their phenotype and why oral corticosteroids may not always be the best treatment option for all exacerbation of symptoms in individuals with severe asthma. Recent findings Studies dating back to the 1990s showed that asthma exacerbations across the spectrum of asthma severity were of different inflammatory endotypes. In addition, there is a wealth of evidence suggesting that eosinophilic inflammation is very responsive to corticosteroid therapy, but that non-eosinophilic inflammation is less so. Two recent UK-based studies have undertaken systematic phenotyping of exacerbations in severe asthma and have shown that there are a significant minority of exacerbation events with an increase in asthma symptoms, fall in lung function, but without evidence of raised T2 biomarkers. Summary The evidence to date would suggest that T2 biomarker low asthma exacerbations do not benefit from the administration of oral corticosteroids; in fact, the effect of the oral corticosteroids is harmful. However, there is a paucity of data to answer this question directly. Further research is needed to assess the evolution of non-T2 exacerbations not treated with OCS in a randomised, placebo-controlled, manner.

show abstract

Section: Introductionmentioning

confidence: 99%

Asthma Exacerbations in Severe Asthma: Why Systemic Corticosteroids May not Always Be the Best Treatment Option

McDowell

Busby

Heaney

2023

Curr Treat Options Allergy

View full text Add to dashboard Cite

show abstract

“…Aerosolised hydrocortisone in low dosage has produced encouraging results in the treatment of human bronchial asthma (Foulds, Greaves, Herxheimer & Kingdom, 1955;Helm & Heyworth, 1958), the most satisfactory results being in patients with allergic asthma without hypersecretion. A comparison of the anti-anaphylactic effects of ethanolamine and hydrocortisone administered by aerosol to guinea-pigs was therefore made.…”

mentioning

confidence: 99%

A comparison of the anti-anaphylactic properties of ethanolamine and hydrocortisone

Goadby

Smith

1965

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

A comparison of the anti-anaphylactic properties of ethanolamine and hydrocortisone P. GOADBY AND W. G. SMITH Both ethanolamine and hydrocortisone potentiate the anti-anaphylactic activity of mepyramine in actively sensitised guinea-pigs subjected to anaphylactic shock by exposure to aerosols of antigen solution. The effects of these two substances have now been compared. After intramuscular injection, the peak effect with ethanolamine occurred 1 hr later whereas with hydrocortisone it occurred 18 hr later. Both substances were also effective, after 45 min and 12 hr respectively, as aerosols. The optimum intramuscular dose of ethanolamine was 10 mg/kg and that of hydrocortisone 100 mg/kg. After aerosol administration, optimum effects were observed when 5% solutions of either drug were used.ORTISONE and synthetic analogues have been used successfully

show abstract

Aerosol Steroid Therapy and Chronic Bronchial Asthma

Bickerman¹

1963

JAMA

View full text Add to dashboard Cite

Inhalation of Hydrocortisone Acetate for Bronchial Asthma

Cited by 19 publications

References 3 publications

Asthma Exacerbations in Severe Asthma: Why Systemic Corticosteroids May not Always Be the Best Treatment Option

Asthma Exacerbations in Severe Asthma: Why Systemic Corticosteroids May not Always Be the Best Treatment Option

A comparison of the anti-anaphylactic properties of ethanolamine and hydrocortisone

Aerosol Steroid Therapy and Chronic Bronchial Asthma

Contact Info

Product

Resources

About